All News about Day One Biopharmaceuticals Inc
What 7 Analyst Ratings Have To Say About Day One Biopharmaceutical
January 09, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/01/09/dawn_logo_light__9c308943a89a754da8350168ab16d381.png?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/4b416a9e-66eb-4bda-aef9-e929b3c00eb9/small/dayonebio-logo-rgb-square-large-jpg.jpg)
![](https://ml.globenewswire.com/media/4b416a9e-66eb-4bda-aef9-e929b3c00eb9/small/dayonebio-logo-rgb-square-large-jpg.jpg)
Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022
Via GlobeNewswire
![](https://cdn.benzinga.com/files/images/story/2022/12/14/dawn_logo_light__9c308943a89a754da8350168ab16d381.png?width=1200&height=800&fit=crop)
This Pediatric Cancer Company Makes It To Analyst's Conviction List
December 14, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/06/23/image_2.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_30794.jpeg?width=1200&height=800&fit=crop)
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
December 15, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
December 14, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_8593.png?width=1200&height=800&fit=crop)
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
December 05, 2022
Via Benzinga
![](https://ml.globenewswire.com/media/4b416a9e-66eb-4bda-aef9-e929b3c00eb9/small/dayonebio-logo-rgb-square-large-jpg.jpg)
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
December 01, 2022
Via Benzinga
![](https://ml.globenewswire.com/media/4b416a9e-66eb-4bda-aef9-e929b3c00eb9/small/dayonebio-logo-rgb-square-large-jpg.jpg)
![](https://ml.globenewswire.com/media/4b416a9e-66eb-4bda-aef9-e929b3c00eb9/small/dayonebio-logo-rgb-square-large-jpg.jpg)
![](https://ml.globenewswire.com/media/4b416a9e-66eb-4bda-aef9-e929b3c00eb9/small/dayonebio-logo-rgb-square-large-jpg.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/valuestock_image_2720.jpeg?width=1200&height=800&fit=crop)
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
October 12, 2022
Exposures
COVID-19
![](https://cdn.benzinga.com/files/images/story/2022/08/12/image30.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/08/15/image29.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/08/12/image34.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_13024.jpeg?width=1200&height=800&fit=crop)
![](https://images.pexels.com/photos/2280549/pexels-photo-2280549.jpeg?auto=compress&cs=tinysrgb&h=750&w=1260)
![](https://cdn.benzinga.com/files/images/story/2022/06/22/biotech3.jpg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU4.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/06/15/biotech11.jpg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2019/09/pills-1.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/06/14/biotech2.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_10445.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/06/14/price_targets.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/06/14/yesterdays_movers.png?width=1200&height=800&fit=crop)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.